MerusMRUS
MRUS
About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Employees: 229
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
50% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 50
6% more funds holding
Funds holding: 177 [Q2] → 187 (+10) [Q3]
3.46% less ownership
Funds ownership: 104.66% [Q2] → 101.2% (-3.46%) [Q3]
16% less capital invested
Capital invested by funds: $4.1B [Q2] → $3.45B (-$649M) [Q3]
20% less call options, than puts
Call options by funds: $12.2M | Put options by funds: $15.3M
37% less funds holding in top 10
Funds holding in top 10: 19 [Q2] → 12 (-7) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$73
75%
upside
Avg. target
$90
117%
upside
High target
$111
167%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz 25% 1-year accuracy 11 / 44 met price target | 133%upside $97 | Buy Maintained | 9 Dec 2024 |
Needham Ami Fadia 47% 1-year accuracy 78 / 165 met price target | 104%upside $85 | Buy Reiterated | 9 Dec 2024 |
Guggenheim Michael Schmidt 17% 1-year accuracy 4 / 23 met price target | 167%upside $111 | Buy Maintained | 5 Dec 2024 |
HC Wainwright & Co. Andrew Fein 35% 1-year accuracy 121 / 343 met price target | 104%upside $85 | Buy Reiterated | 5 Dec 2024 |
Goldman Sachs Richard Law 17% 1-year accuracy 1 / 6 met price target | 75%upside $73 | Buy Initiated | 21 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications.
Neutral
GlobeNewsWire
3 weeks ago
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies.
Neutral
GlobeNewsWire
1 month ago
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5.
Neutral
GlobeNewsWire
1 month ago
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025
Positive
Benzinga
2 months ago
Merus Scores Its First FDA Approval For Lung Cancer Drug
On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Neutral
GlobeNewsWire
2 months ago
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI® has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction.1 See Important Safety Information below.
Positive
Reuters
2 months ago
US FDA approves Merus' therapy to treat lung, pancreatic cancers
The U.S. Food and Drug Administration approved Merus NV's therapy to treat patients with types of lung and pancreatic cancers on Wednesday.
Neutral
GlobeNewsWire
2 months ago
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the United States (U.S.).
Neutral
GlobeNewsWire
2 months ago
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC
Positive
Schaeffers Research
2 months ago
Biotech Stock Boosted on Brand-New 'Buy' Rating
Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating.
Charts implemented using Lightweight Charts™